Robb Edward J, Tucker Cassius M, Corley Lane, Bryson W Lawrence, Rogers Karen C, Sturgess Kynan, Bade Donald J, Brodersen Bruce
Pfizer Animal Health, Kalamazoo, MI 49001, USA.
Vet Ther. 2007 Summer;8(2):127-35.
After undergoing arrival processing at one of two commercial feedlots, feeder calves with clinical signs of bovine respiratory disease (BRD) were randomly assigned to receive either tulathromycin (2.4 mg/kg SC) or enrofloxacin (12.5 mg/kg SC). Additional therapy for calves that did not respond to initial treatment followed a prescribed course. Initial treatment with tulathromycin resulted in significantly higher (P = .009 and P = .031 at sites 1 and 2, respectively) therapeutic success (87.9% and 80%, respectively) than did initial treatment with enrofloxacin (70.2% and 62.5%, respectively). Animals treated with tulathromycin also had fewer subsequent treatments and higher weight gains compared with those treated with enrofloxacin.
在两个商业饲养场之一进行入场处理后,出现牛呼吸道疾病(BRD)临床症状的育肥牛犊被随机分配接受图拉霉素(2.4毫克/千克皮下注射)或恩诺沙星(12.5毫克/千克皮下注射)。对初始治疗无反应的犊牛的额外治疗遵循规定疗程。与恩诺沙星初始治疗相比,图拉霉素初始治疗导致的治疗成功率显著更高(分别在第1和第2个地点,P = 0.009和P = 0.031)(分别为87.9%和80%),恩诺沙星初始治疗的成功率分别为70.2%和62.5%。与用恩诺沙星治疗的动物相比,用图拉霉素治疗的动物后续治疗次数更少,体重增加更多。